PT - JOURNAL ARTICLE AU - REINHARD E. FRIEDRICH AU - FALK WÜSTHOFF AU - ANDREAS M. LUEBKE AU - FELIX K. KOHLRUSCH AU - ILSE WIELAND AU - MARTIN ZENKER AU - MARTIN GOSAU TI - <em>KRAS</em> Mutation in an Implant-associated Peripheral Giant Cell Granuloma of the Jaw: Implications of Genetic Analysis of the Lesion for Treatment Concept and Surveillance AID - 10.21873/invivo.12335 DP - 2021 Mar 01 TA - In Vivo PG - 947--953 VI - 35 IP - 2 4099 - http://iv.iiarjournals.org/content/35/2/947.short 4100 - http://iv.iiarjournals.org/content/35/2/947.full SO - In Vivo2021 Mar 01; 35 AB - The aim of this case report was to detail diagnosis and therapy in a case of implant-associated peripheral giant cell granuloma (IA-PGCG) of the jaw. Case Report: The 41-year-old female attended the outpatient clinic for treatment of recurrent mandibular IA-PGCG. The lesion was excised and the defect was closed with a connective tissue graft of the palate. Healing of oral defects was uneventful, and no local recurrence has occurred during a follow-up of 7 months. Genetic examination of the lesion identified a somatic mutation in KRAS. Conclusion: The lesions are assessed as reactive-inflammatory changes in the mucous membrane of the oral cavity. The cause of the lesion is unknown. KRAS mutations are commonly found in various cancer tissues, but also in germline and mosaic RASopathies. Recently, KRAS mutations have been identified in several IA-PGCG. The clinical course of a frequently locally recurring lesion gives rise to the assumption that lesions of this type show characteristics known in benign neoplasms.